Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology

Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology

Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemakerEnrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) leadConduction System…

Abbott announces advancements in AVEIR Conduction System pacing technology

Abbott has announced significant developments in its AVEIR Conduction System Pacing (CSP) technology, which were presented during the Heart Rhythm Society's 46th annual meeting in San Diego and published in the Heart Rhythm Journal. The highlight was the successful results from Abbott's AVEIR CSP acute clinical feasibility study, which is the first in-human study to assess a leadless pacemaker delivering conduction pacing to the heart's left bun…